

Special Issue

Multitargeting Agents for Alzheimer's Disease

Message from the Guest Editors

As life-expectancy gets higher, we are experiencing a dramatically increasing burden of age-related diseases for healthcare. Among these, Alzheimer's disease (AD) represents a devastating, ultimately fatal neurodegenerative syndrome, the effective treatment of which remains elusive. The complex, multifaceted nature of AD prompted researchers to follow a paradigm shift towards multitargeting compounds, single molecular entities intentionally designed to correct two or more relevant AD deficits upon exerting different bioactivities with cooperative or additive effect. This Special Issue aims to provide an overview of recent studies focused on innovative approaches to treat AD by means of multifunctional molecules able to modulate multiple disease-related targets as candidates for developing disease-modifying drugs.

Guest Editors

Dr. Leonardo Pisani

Department of Pharmacy-Drug-Sciences, University of Bari Aldo Moro, 70125 Bari, Italy

Dr. Modesto De Candia

Department of Pharmacy-Pharmaceutical Sciences, University of Bari, Bari, Italy

Deadline for manuscript submissions

closed (30 September 2023)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/81012

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).